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Abstract
Central venous catheters (CVCs) account for the largest proportion of thrombotic events in pedi-
atric patients. Questions remain regarding adequate treatment and preventionmethods.We sur-
veyed pediatric hematology/oncology specialists, using hypothetical cases to assess management
strategies for acute CVC thrombosis and secondary prevention. Survey respondents varied in the
use of the thrombophilia evaluation (33.3%, 41/123) and duration of treatment (6 weeks: 54.1%,
66/122). SecondaryCVCprophylaxiswas utilized by36.6% (45/123) of respondents andby24.4%
(30/123) but only if there was a documented thrombophilia. This heterogeneity highlights the
need for clinical studies to address these important clinical questions.
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1 INTRODUCTION
The presence of a central venous catheter (CVC) is the most signifi-
cant risk factor for deep vein thrombosis (DVT) in pediatric patients.1,2
Thrombotic events related to CVCs can lead to significant compli-
cations including loss of venous access, pain, swelling, postthrom-
botic syndrome, and potentially death from a pulmonary embolism.
CVC-associated DVT is an increasing pediatric problem and questions
remain regarding the most effective way to treat and prevent recur-
rent CVC-related thrombosis.3 This case-based survey was designed
to assess current management strategies for pediatric patients with a
CVC thrombosis with a focus on the use of the thrombophilia evalua-
tion, duration of anticoagulation, and the use of secondary prophylaxis.
We hypothesize that there will be significant variation in these three
management areas secondary to a current lack of clinical data.
2 METHODS
A case-based survey was developed by the authors targeting the
three management areas of interest including the use of the throm-
bophilia evaluation, duration of treatment, and the use of secondary
Abbreviations: ASPHO, American Society of Pediatric Hematology/Oncology; CHEST
guidelines, American College of Chest Physicians 9th edition treatment guidelines; CVC,
central venous catheter; DVT, deep vein thrombosis
TABLE 1 Respondent demographics
Respondent variable Total, n= 140 (%)
Type of practice
Hematology and oncology 119 (85)
Hematology 16 (11.4)
Oncology 5 (3.6)
Years in practice
Fellow 20 (14.3)
0–5 38 (27.1)
6–10 27 (19.3)
11–15 15 (10.7)
>15 40 (28.6)
Annual number of thrombosis patients at respondent’s center
0–10 20 (14.3)
10–50 73 (52.1)
50–100 33 (23.6)
>100 14 (10)
prophylaxis. The survey was piloted in the authors’ institution and
revised based on respondent feedback. The final survey was posted
twice (May 27, 2015 and June 10, 2015) on the American Soci-
ety of Pediatric Hematology/Oncology (ASPHO) clinical forum. The
survey included three demographic questions regarding number of
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TABLE 2 Case scenario responses
Case 1: A 2-year-old female child is admitted for severe dehydration from viral gastroenteritis. A CVC is placed, and she develops a symptomatic
CVC-associated deep vein thrombosis in her right subclavian vein. This is her first thrombotic event and there is no family history of thrombosis.
Questions Responses
Would you perform a thrombophilia evaluation?
Yes 41/123 (33.3%)
No 82/123 (66.7%)
Would you stop anticoagulation at 6 weeks if the ultrasound demonstrates thrombus resolution?
Yes 66/122 (54.1%)
Yes, but only if the thrombophilia evaluation is normal 16/122 (13.1%)
Yes, but start aspirin 2/122 (1.6%)
No, treat for 12weeks 38/122 (31.2%)
A year later she is admitted to the intensive care unit with a severe asthma exacerbation requiring placement of a newCVC.Would you place her on
anticoagulation to prevent a CVC-associated thrombosis?
Yes 45/123 (36.6%)
Yes, but only if there was an identified thrombophilia 30/123 (24.4%)
No 48/123 (39%)
If applicable what secondary prophylactic regimenwould you use?
Prophylactic dosing of enoxaparin 66/113 (58.4%)
Therapeutic dosing of enoxaparin 7/113 (6.2%)
Unfractionated heparin prophylactic dosing (10 units/kg/hr) 1/113 (0.9%)
Warfarin (INR goal 1.5–2.5) 1/113 (0.9%)
Aspirin 2/113 (1.7%)
Not applicable 36/113 (31.9%)
Case 2: A 6-year-old female child with standard risk acute lymphoblastic leukemia (B-precursor) just completed 3months of anticoagulation for a
symptomatic CVC-associated clot in the setting of asparaginase therapy during delayed intensification. She is now in themaintenance phase of therapy.
Questions Responses
A repeat US demonstrates clot resolution. The same CVC remains in place.Would you continue anticoagulation for the duration of the CVC?
No 77/119 (64.7%)
If applicable what secondary prophylactic regimenwould you use?
Prophylactic dosing of enoxaparin 35/116 (30.2%)
Therapeutic dosing of enoxaparin 6/116 (5.2%)
Warfarin (INR goal 1.5–2.5 or low dose no INR goal) 3/116 (2.6%)
Aspirin 2/116 (1.7%)
Not applicable 70/116 (60.3%)
What if the initial CVC that resulted in the thrombotic event was removed but she now has a newCVC in place.Would you continue anticoagulation for
the newCVC?
No 87/119 (73.1%)
CVC, central venous catheter.
years in practice, patient population, and annual number of throm-
bosis patients at the respondent’s center. Case scenarios with CVC-
associated thrombosiswere utilized (Table 2). Casemanagement ques-
tions included the use of a thrombophilia evaluation, duration of anti-
coagulation therapy, and the use of secondary anticoagulation prophy-
laxis with continued or subsequent CVC placement.
Demographic characteristics were summarized by percentages.
Summary statistics for case-based responses were reported using per-
centages. Proportion of case-based responses were compared using
either Fisher’s exact test or the 𝜒2 test separated by respondent fac-
tors including total years in practice and annual number of thrombosis
patients.
3 RESULTS
There were a total of 140 responses. The majority (90%, 126/140)
werewith the first posting. ASPHO reported 1,829 eligible subscribers
at the time of posting; we are unable to determine how many actu-
ally viewed the posting. Table 1 provides a summary of the respon-
dent’s demographics. The case description and responses to manage-
ment questions are provided in Table 2.
In case 1, a 2-year-old female child with a CVC-associated upper
extremity DVT in the setting of an acute illness, 33.3% (41/123) of
respondents performed a thrombophilia evaluation; 54.1% (66/122)
stopped anticoagulation at 6 weeks after demonstration of clot
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resolution without a thrombophilia evaluation, whereas 13.1% (16/
122) discontinued at 6 weeks if the thrombophilia evaluation was
normal. The patient in case 1 required subsequent CVC placement a
year later and 36.6% (45/123) placed her on anticoagulation for sec-
ondary prophylaxis, whereas 24.4% (30/123) only used anticoagula-
tion if there was a previously identified thrombophilia.
In case 2, a 6-year-old female child with acute lymphoblastic
leukemia with a CVC-associated thrombosis in delayed intensification
completed 3 months of anticoagulation with clot resolution but the
same CVC remains in place; 64.7% (77/119) of respondents discon-
tinued anticoagulation. If the subject had a new CVC in place, 73.1%
(87/119) did not continue anticoagulation.
Responses for each case were analyzed by respondent factors,
including total years in practice and annual number of thrombosis
patients. No statistical difference was detected in the proportion of
responses by each respondent factor.
4 DISCUSSION
In this survey of pediatric hematologist/oncologists, using specific
cases to elicit responses, there was significant variation in the use
of the thrombophilia evaluation, duration of treatment for a CVC-
associated thrombosis (6 weeks vs. 3 months), and the use of sec-
ondary CVC prophylaxis. One-third of respondents sent a throm-
bophilia evaluation for a patient with a CVC-associated thrombosis. In
this clinical setting, debate remains about the utility of thrombophilia
testing. The most widely used reference for the management of pedi-
atric thrombosis, the AmericanCollege of Chest Physicians 9th edition
treatment guidelines (CHEST guidelines), comments that the presence
or absenceof a thrombophilia risk factor should not influence thedura-
tion and intensity of treatment.4 Guidelines from the United Kingdom
aremoredefinitive and state that a thrombophilia evaluation is not rec-
ommended inpatientswith aCVC-associated thrombosis.5 In contrast,
our survey demonstrated that not only did one-third of respondents
send a thrombophilia evaluation but they used this testing to direct
both duration of therapy andwhether secondary prophylaxis was indi-
cated for future line placements.
Over half (54%) of respondents stopped anticoagulation after
6 weeks of therapy if there was clot resolution. This is in contrast to
the current CHEST guidelines that recommend a treatment duration
of 3 months.4 This recommendation is extrapolated from a random-
ized clinical trial of 900adult patientswithDVTwhereDVT recurrence
was higher (18.1%) in the 6-week treatment group as compared to the
6-month group (9.5%).6 Interestingly, a subgroup analysis of this trial
demonstrated decreased recurrence rates in those subjectswith a pro-
voked DVT.6 Currently, there are no published studies comparing the
duration of anticoagulation in pediatric patients. We await the results
of the ongoing KIDS-DOTT study, which is investigating the safety and
efficacy of limited treatment duration (6weeks vs. 3months) in the set-
ting of a provoked DVT in pediatric patients.7
There was a wide variation in the reported use of secondary CVC
DVT prophylaxis. For case 2, a 6-year-old female child with acute
lymphoblastic leukemia, the majority of respondents (64.7%, 77/119)
would not continue anticoagulation after 3 months of therapy even if
the same line remained in place. This is despite the CHEST guidelines
recommendation to continue anticoagulation, at prophylaxis dosing, if
the CVC remains in place after completing the acute DVT treatment
course.4 In contrast, for case 1 when the second CVC was placed in
the setting of an acute illness a year after the initial CVC-associated
thrombotic event, a higher proportion of respondents (61%) would
consider prophylaxis. The 2012 CHEST guidelines recommend against
primary prophylaxis after the placement of a central venous line but
do not specifically comment on secondary prophylaxis.4 The lack of
high-quality evidence in children leaves clinicians with only clinical
judgment and experience to guide their management. There are three
randomized clinical trials that studied primary CVC prophylaxis in
pediatric patients using prophylactic dosing of either low molecu-
lar weight heparin (anti-Xa goal 0.1–0.3), unfractionated heparin (10
units/kg/hr), or warfarin (INR goal 1.3–1.9).8–10 None of these trials
were able to demonstrate a difference in thrombotic events between
the two treatment arms, although these studies were generally under-
powered. A recent systematic review and meta-analysis of thrombo-
prophylaxis in children was unable to find evidence that thrombo-
prophylaxis reduced the risk of CVC-related thrombosis.11 Ongoing
research is needed to determine the most effective way to prevent
both primary and secondary CVC-associated thrombosis.
Limitations of this study include that physicians’ self-reporting with
a hypothetical situation may differ from their actual management. In
addition, as only 140 providers responded to the forum posting, that
may represent a biased sample and not fully represent current antico-
agulant strategies of all pediatric hematologists/oncologists.
5 CONCLUSION
This case-based survey demonstrated significant variation in the man-
agement of CVC-associated thrombosis and in the use of secondary
CVC DVT prophylaxis highlighting the need for ongoing clinical stud-
ies to address these important clinical questions.
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